Navigation Links
Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant
Date:1/7/2011

CHADDS FORD, Pa., Jan. 7, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its new formulation of OPANA® ER designed to be crush resistant.  The complete response letter did not require that additional clinical studies be conducted for approval of the NDA.

"As a result of ongoing discussions with FDA, we have begun to address the issue from the complete response letter and will work closely with the agency to finalize our response," said Dr. Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We are confident that we can address the issue set forth, currently anticipate responding to the FDA by mid 2011 and would expect a six month review cycle once our response is filed.  We remain focused on bringing this new formulation of OPANA ER to market for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time."

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit w
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)... May 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI ... terms of the agreement, Isis is eligible to receive ... immediate $100 million up-front payment and a $55 million ... 2 study in patients with compromised kidney function. Isis ...
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... Inc. (NYSE Amex: ANX ) today announced that ... at the 10th Annual BIOInvestor Forum Conference on Wednesday, October ... Cliff Salon at the Palace Hotel in San Francisco. ... and slide presentation on the ADVENTRX Pharmaceuticals web site at ...
... Innocoll, Inc. announced it has entered into a ... for CollaGUARD surgical adhesion barrier for the prevention of ... Dr. Michael Myers, President and CEO stated "This ... an increasingly important and dynamic market for medical products ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3
(Date:5/4/2015)... 05, 2015 The National Association ... Betancourt as a 2015-2016 inductee into the NAPW ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor," said NAPW President Star Jones. ...
(Date:5/4/2015)... Every Friday afternoon at A Forever ... Southwest Michigan, patients and staff gather in the common ... rehabilitation program and to gain encouragement and inspiration in ... One by one, those patients who have completed their ... certificates and to share a bit about their journey ...
(Date:5/4/2015)... Montreal, CANADA (PRWEB) May 04, 2015 ... development of innovative proofreading technologies, today announced that ... #438 at the Music City Center, in Nashville ... Proofware is the world's first true all-in-one we-based ... everyone involved in the security of their brand ...
(Date:5/4/2015)... City, MO (PRWEB) May 04, 2015 ... vice president and chief physician executive, and William C. ... have received and accepted personal invitations from the Secretary ... National Security Forum (NSF) at the Air War College, ... is to expose influential citizens to senior U.S. and ...
(Date:5/4/2015)... Milton Hershey School® has named J. ... the Year, recognizing his commitment to pediatric cancer research ... for MHS students. , “Dr. Graves is a tremendous ... are provided a top-notch education, a nurturing environment, and ... Pete Gurt ’85, president of MHS. “He is applying ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2
... Free from LTC Financial Partners, KIRKLAND, Wash., ... care,for an incapacitated parent or spouse, the impact ... estate or inheritance. And your loved,one,s daily needs ... *(PHOTO 72dpi: Send2Press.com/mediaboom/08-0227-JonasRoeser_72dpi.jpg), *(Photo Caption: LTC Senior ...
... Israel, Feb. 27 Shamir,Optical Industry Ltd. (Nasdaq: ... year end 2007 earnings results on Thursday, March 6, ... results at 9:00 A.M. EST,that morning., The conference ... To,listen live, please go to http://www.kcsa.com approximately ...
... 2008 -- A new study led by researchers at the ... diabetes who reported taking less insulin than prescribed had a ... complications than those who did not skip needed insulin shots. ... Care. , The study highlights the dangers of insulin restriction ...
... new article suggests that the United States government ... Cuba into a biomedical research institute dedicated to ... the open-access journal PLoS Neglected Tropical Diseases, Editor-in-Chief ... be in an optimal position to directly address ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") announced ... A. Cafaro, and Executive Vice,President and Chief Investment Officer, ... at the Citi 2008 Global Property CEO,Conference in Palm ... p.m.,Eastern Time., Those wishing to access the presentation ...
... Kansas City-based company connects, educates and entertains sports ... Sports enthusiasts have a new,online hotspot with Kansas ... have collaborated to produce AthletixNation.com, the premier,community for ... ultimate goal of AthletixNation.com is to have a ...
Cached Medicine News:Health News:Long Term Care Newsletter Helps Preserve Solvency & Sanity While Caring for Loved One 2Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2007 Earnings Results 2Health News:Joslin study finds restricting insulin doses increases mortality risk 2Health News:Joslin study finds restricting insulin doses increases mortality risk 3Health News:From detainee facility to health advocacy center: A new role for Guantanamo? 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... offer a spill-proof design and effective output, ... angle. All medical nebulizers are free-standing for ... configurations are available., ,All Portex® medication ... medication nebulizers feature consistently fine misting and ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
Medicine Products: